⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505792 | 0.92 | — | — | |
| SCHEMBL5416696 | 0.92 | — | — | |
| SCHEMBL6050422 | 0.66 | ADH1B (0.31) | — | |
| SCHEMBL8861096 | 0.65 | — | — | |
| SCHEMBL4591211 | 0.64 | — | — | |
| SCHEMBL6903892 | 0.64 | — | — | |
| SCHEMBL8040334 | 0.61 | — | — | |
| SCHEMBL38101 | 0.60 | — | — | |
| SCHEMBL11671983 | 0.58 | — | — | |
| SCHEMBL323151 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051983-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2009-04-29 | — | — | EP | claimed |
| WO-2008020024-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2008-02-21 | — | — | WO | claimed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9428489-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-7256294-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| EP-1385835-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085868-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| US-5693634-A | FOR SYSTEMIC AND TOPICAL TREATMENT OF HUMANS AND ANIMALS; VETERINARY MEDICINE | GLAXO WELLCOME S.P.A. (IT) | 1997-12-02 | — | — | US | disclosed |